{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T04:32:09Z","timestamp":1754109129563,"version":"3.37.3"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T00:00:00Z","timestamp":1611100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T00:00:00Z","timestamp":1611100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Can J Emerg Med"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s43678-020-00054-y","type":"journal-article","created":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T10:03:26Z","timestamp":1611137006000},"page":"325-329","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Anticoagulation for newly diagnosed atrial fibrillation and 90-day rates of stroke and bleeding"],"prefix":"10.1007","volume":"23","author":[{"given":"Saghar","family":"Niaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Kirwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha","family":"Clayton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathew","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2763-6474","authenticated-orcid":false,"given":"Kerstin","family":"de Wit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,20]]},"reference":[{"issue":"8","key":"54_CR1","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","volume":"129","author":"SS Chugh","year":"2014","unstructured":"Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation. 2014;129(8):837\u201347.","journal-title":"Circulation"},{"key":"54_CR2","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.cjca.2014.08.001","volume":"30","author":"A Verma","year":"2014","unstructured":"Verma A, Cairns JA, Mitchell BL, et al. 2014 focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation. Can J Cardiol. 2014;30:1114\u201330.","journal-title":"Can J Cardiol"},{"key":"54_CR3","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C, The Subcommittee on Control of Anticoagulation of the International Society of Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692\u20134.","journal-title":"J Thromb Haemost."},{"issue":"217","key":"54_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ijcard.2016.04.173","volume":"15","author":"L Fauchier","year":"2016","unstructured":"Fauchier L, Chaize G, Gaudin AF, Vainchtock A, Rushton-Smith SK, Cotte FE. Predictive ability of HAS-BLED, HEMORR2HAGESm and ATRIA bleeding risk scores in patients with atrial fibrillation. A French nationwide cross-sectional study. Int J Cardiol. 2016;15(217):85\u201391.","journal-title":"Int J Cardiol"},{"issue":"9","key":"54_CR5","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/j.amjcard.2017.07.051","volume":"120","author":"X Yao","year":"2017","unstructured":"Yao X, Gersh B, Sangaralingham L, et al. Comparison of the CHA2DS2-VASc, CHADS2, HAS-BLED, ORBIT, and ATRIA risk scores in predicting non-vitamin K agonist oral anticoagulants-associated bleeding in patients with atrial fibrillation. Am J Cardiol. 2017;120(9):1549\u201356.","journal-title":"Am J Cardiol"},{"issue":"2","key":"54_CR6","first-page":"119","volume":"52","author":"A Agresti","year":"1998","unstructured":"Agresti A, Coull BA. Approximate is better than \u201cexact\u201d for interval estimation of binomial proportions. Am Stat. 1998;52(2):119\u201326.","journal-title":"Am Stat"},{"issue":"3","key":"54_CR7","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1017\/cem.2017.418","volume":"20","author":"D Barbic","year":"2018","unstructured":"Barbic D, DeWitt C, Harris D, et al. Implementation of an emergency department atrial fibrillation and flutter pathway improves rates of appropriate anticoagulation, reduces length of stay and thirty-day revisit rates for congestive heart failure. Can J Emerg Med. 2018;20(3):392\u2013400.","journal-title":"Can J Emerg Med"},{"issue":"1","key":"54_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.annemergmed.2014.07.016","volume":"65","author":"B Col-Vinent","year":"2015","unstructured":"Col-Vinent B, Martin A, Malagon F, Suero C, Sanchez J, Varona M, et al. Stroke prophylaxis in atrial fibrillation: searching for management improvement opportunities in the emergency department: the HERMES-AF study. Ann Emerg Med. 2015;65(1):1\u201312.","journal-title":"Ann Emerg Med"},{"issue":"4","key":"54_CR9","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.annemergmed.2015.03.024","volume":"66","author":"CL Atzema","year":"2015","unstructured":"Atzema CL, Austin PC, Chong AS, Pharm AJ. The long-term use of warfarin among atrial fibrillation patients discharged from an emergency department with a warfarin prescription. Ann Emerg Med. 2015;66(4):347\u201354.","journal-title":"Ann Emerg Med"},{"issue":"4","key":"54_CR10","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.annemergmed.2018.09.001","volume":"73","author":"K Magee","year":"2019","unstructured":"Magee K, McCullen M, Clory M, et al. The Canadian community utilization of stroke prevention study in atrial fibrillation in the emergency department (C-CUSP ED). Ann Emerg Med. 2019;73(4):382\u201392.","journal-title":"Ann Emerg Med"},{"issue":"5","key":"54_CR11","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.annemergmed.2016.10.013","volume":"69","author":"G Stiell","year":"2017","unstructured":"Stiell G, Clement CM, Rowe BH, et al. Outcomes for emergency department patients with recent onset atrial fibrillation and flutter treated in Canadian hospitals. Ann Emerg Med. 2017;69(5):562-571.e2.","journal-title":"Ann Emerg Med"},{"issue":"3","key":"54_CR12","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1017\/cem.2018.26","volume":"20","author":"IG Stiell","year":"2018","unstructured":"Stiell IG, Scheuermeyer FX, Vadeboncoeur A, et al. CAEP acute atrial fibrillation\/flutter best practices checklist. CJEM. 2018;20(3):334\u201342.","journal-title":"CJEM"},{"issue":"11","key":"54_CR13","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.cjca.2018.08.026","volume":"34","author":"JG Andrade","year":"2018","unstructured":"Andrade JG, Verma A, Mitchell LB, et al. 2018 focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation. Can J Cardiol. 2018;34(11):1371\u201392.","journal-title":"Can J Cardiol"}],"container-title":["Canadian Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43678-020-00054-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43678-020-00054-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43678-020-00054-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T22:13:39Z","timestamp":1620339219000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43678-020-00054-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,20]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["54"],"URL":"https:\/\/doi.org\/10.1007\/s43678-020-00054-y","relation":{},"ISSN":["1481-8035","1481-8043"],"issn-type":[{"type":"print","value":"1481-8035"},{"type":"electronic","value":"1481-8043"}],"subject":[],"published":{"date-parts":[[2021,1,20]]},"assertion":[{"value":"14 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Bayer manufacture rivaroxaban which is an anticoagulant used in the prevention of stroke for patients with atrial fibrillation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}